Patent details

Basic Information

Publication number:

EP2924034

PCT Application Number:

Type:

European Patent Granted for LU

Legal Status:

In force

Application number:

EP151573482

PCT Publication Number:

First applicant's nationality:

Translation Language:

EPO Publication Language:

English

English Title of Invention:

PHARMACEUTICAL COMPOSITION COMPRISING A NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR

French Title of Invention:

COMPOSITION PHARMACEUTIQUE COMPRENANT UN INHIBITEUR NON NUCLÉOSIDIQUE DE TRANSCRIPTASE INVERSE

German Title of Invention:

PHARMAZEUTISCHE ZUSAMMENSETZUNG MIT EINEM NICHTNUKLEOSIDISCHEN REVERSE-TRANSKRIPTASEHEMMER

SPC Number:

LUC00114

Dates

Filing date:

28/03/2011

Grant date:

02/11/2016

EP Publication Date:

02/11/2016

PCT Publication Date:

Claims Translation Received Date:

Translations Received Date (B1 EP Publication):

Translations Received Date (B2 EP Publication):

Translations Received Date (B3 EP Publication):

Publication date:

30/09/2015

EP B1 Publication Date:

02/11/2016

EP B2 Publication Date:

EP B3 Publication Date:

Lapsed date:

Expiration date:

28/03/2031

Renunciation date:

Revocation date:

Annulment date:

Owner

From:

28/03/2011

 

 

Name:

Merck Canada Inc.

Address:

16711 Trans-Canada Highway, Kirkland QC H9H 3L1, Canada (CA)

Inventor

1

Name:

Burch Jason

Address:

United States (US)

2

Name:

Cote Bernard

Address:

Canada (CA)

Priority

1

Priority Number:

318824 P

Priority Date:

30/03/2010

Priority Country:

United States (US)

2

Priority Number:

321573 P

Priority Date:

07/04/2010

Priority Country:

United States (US)

Classification

Main IPC Class:

C07D 401/06;

Annual Fees

Annual Fee Due Date:

31/03/2026

Annual Fee Number:

16

Annual Fee Amount:

230 Euro

Expected Payer:

Last Annual Fee Payment Date:

12/02/2025

Last Annual Fee Paid Number:

15

Last Annual Fee Paid Amount:

213 Euro

Payer:

MASTER DATA CENTER INC (ex Clarivate Analytics)

Filing date	Document type	Number of pages